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ABSTRACT
Objective: To determine if low-dose weekly
chloroquine (CQ) therapy improves recovery from
malaria-associated anaemia.
Design: Proof of concept randomised clinical trial.
Setting: West Kiang District, Lower River Region,
The Gambia.
Participants: Children resident in participating
communities, aged 12–72 months, with
uncomplicated malaria identified using active case
detection over two consecutive malaria transmission
seasons.
Interventions: In 2007, eligible children were
randomised to chloroquine-sulfadoxine/pyrimethamine
(CQ-SP) or co-artemether (ACT) antimalarial therapy,
and after parasite clearance on day 3 were
subsequently re-randomised (double-blind) to weekly
low-dose CQ (5 mg/kg) or placebo. In 2008, all eligible
children were treated with ACT and subsequently
randomised to CQ or placebo.
Outcome measures: The primary outcome was a
change in haemoglobin from baseline (day 3 of
antimalarial treatment) to day 90 in the CQ and placebo
treatment arms. Secondary outcomes were changes in
urinary neopterin as a marker of macrophage
activation, markers of erythropoietic response and
prevalence of submicroscopic parasitaemia. Change in
haemoglobin in the placebo arm by initial antimalarial
treatment was also assessed.
Results: In 2007, 101 children with uncomplicated
malaria were randomised to antimalarial treatment
with CQ-SP or ACT and 65 were subsequently
randomised to weekly CQ or placebo. In 2008, all
children received ACT antimalarial treatment and 31
were subsequently randomised to receive weekly
CQ or placebo. Follow-up to day 90 was 96%.
There was no effect of weekly CQ vs placebo on
change in haemoglobin at day 90 (CQ+10.04 g/L
(95% CI 6.66 to 13.42) vs placebo +7.61 g/L (95% CI
2.88 to 12.35)). There was no effect on the secondary
outcomes assessed, or effect of initial antimalarial
therapy on haemoglobin recovery. Higher day 90
haemoglobin correlated independently with older age,
not being stunted, higher haemoglobin at day 0 and
adequate iron status at day 3.
Conclusions: Weekly low-dose CQ after effective
antimalarial treatment is not effective in improving
recovery from postmalarial anaemia.
Trial registration: The clinical trial registration
number is NCT00473837 (ClinicalTrials.gov).
INTRODUCTION
The precise contribution of malaria to
anaemia is difﬁcult to calculate mainly
because many anaemia-causing conditions
coexist in children living in malaria-endemic
countries.1 Murphy and Breman2 estimate
the annual incidence of severe malarial
anaemia (SMA) to be 1.42–5.66 million,
ARTICLE SUMMARY
Article focus
▪ To determine if 3 months of low-dose weekly
chloroquine (CQ) (5 mg/kg) therapy after effect-
ive treatment of uncomplicated malaria can
improve haemoglobin recovery after
malaria-associated anaemia in rural African
children.
▪ To test the hypothesis that chloroquine may
enhance haematological recovery after a malaria
episode through its anti-inflammatory and
immuno-modulatory actions, antimacrophageal
iron loading effect and antimalarial effect
(despite widespread resistance).
Key messages
▪ Weekly low-dose CQ after effective antimalarial
treatment was not effective in improving recovery
from mild-to-moderate postmalarial anaemia.
▪ Weekly low-dose CQ at 5 mg/kg had no clear
effects on erythropoietic responses, as deter-
mined by reticulocyte percentage, or immune-
mediated inflammation as assessed by urinary
neopterin, a marker of macrophage activation.
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resulting in between 194 000 and 974 000 deaths in chil-
dren younger than 5 years of age. SMA increases the risk
of death in children with malaria,3 many of whom die
shortly after admission before blood transfusion can be
started4 5 and after discharge in the community.6 In add-
ition, blood transfusion, the standard treatment for
severe malarial anaemia exposes the child to the risk of
transfusion-related infections like HIV and hepatitis.7
Among a nationally representative sample of children
aged 1–5 years in the Gambia in 1999, 76% had a
haemoglobin (Hb) less than 11 g/dL and 15% had Hb
less than 7 g/dL.8 It is quite likely that most of the cases
of moderate-to-severe anaemia were due in great part to
malaria.9–11 A better understanding of the pathogenesis
of malarial anaemia is required to improve its preven-
tion and management.
Multiple immune and non-immune-mediated mechan-
isms cause anaemia during and after a malarial
episode,12 including the destruction of non-parasitised
erythrocytes, which may account for more than 90% of
erythrocyte loss.13 14 One important component is
inﬂammation-induced iron delocalisation, which is char-
acterised by sequestration of iron by the monocyte–
macrophage system and hepatocytes, resulting in a state
of pseudo-iron deﬁciency, a state that reverses after the
inﬂammation has subsided.12 The trans-membrane
protein ferroportin is the exclusive route for cellular
iron efﬂux and is responsible for releasing absorbed
iron from enterocytes and sequestered iron from macro-
phages.12 15 16 Hepcidin, the master regulator of iron
metabolism which responds both to iron status and
inﬂammation,15 blocks ferroportin. Clinically,
malaria-induced inﬂammation has been shown to be
associated with a hepcidin-mediated reduction in intes-
tinal absorption of iron.17 Inﬂammatory cytokines, par-
ticularly interleukin (IL)-6 and IL-1, stimulate hepcidin
release,18 19 which results both in the reduced iron
absorption of dietary iron and impaired macrophageal
release of iron, the latter effect being quantitatively
much more signiﬁcant as macrophageal iron recycling
and transport to the erythron are 25-fold to 30-fold
greater than the inﬂux of dietary iron. In this way, hepci-
din is the mediator of the anaemia of chronic disease.15
Tumour necrosis factor α could also play a role in
ferroportin-mediated iron transfer independent of hep-
cidin.20 Rapid resolution of malaria-induced inﬂamma-
tion could therefore limit the degree and duration of
malarial anaemia by reducing the duration of iron
delocalisation.
Chloroquine is a cheap and safe antimalarial drug
with proven anti-inﬂammatory properties; it has been
shown to reduce iron delocalisation in vitro.21 22 We
hypothesised that chloroquine may enhance haemato-
logical recovery after a malarial episode through its anti-
inﬂammatory and immuno-modulatory actions, antima-
crophageal iron loading effect and antimalarial effect
(despite widespread resistance). We designed a proof of
concept study to investigate the potential use of chloro-
quine in the management of mild postmalarial anaemia.
MATERIALS AND METHODS
Study design and population
This study was a population-based randomised con-
trolled trial (RCT) in children aged 12–72 months that
was conducted over two malarial seasons in 2007 and
2008 in West Kiang District, Lower River Region, The
Gambia. The study was initially designed and conducted
as a 2×2 randomised placebo-controlled trial in 2007 but
had to be changed, due to changes in the national
malaria treatment guidelines, to a two-arm RCT during
the second malaria transmission season in 2008. In the
2×2 phase of the study, children with malaria were ini-
tially openly randomised to receive a therapeutic dose
regime of chloroquine plus sulfadoxine/pyrimethamine
(CQ-SP) or co-artemether (ACT) (day 0). After treat-
ment, on day 3, children were subsequently randomised
(double blind) to receive weekly chloroquine or placebo
until day 90 (ﬁgure 1). In the two-arm phase, all
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The strengths of this study are its randomised design and
double blinding of the allocation to weekly CQ or placebo and
that few subjects were lost to follow-up. The continuous
follow-up and active case detection for all children ensured
that malarial infections were detected early and within similar
time frames, plus resurgent or new clinical infections were
excluded from the analysis of haemoglobin change. A strict
malaria case definition was adhered to and the measurement
of submicroscopic parasitaemia over time allowed the effects
of incomplete treatment to be modelled.
▪ A limitation of the study was the need to recruit participants
over two malaria transmission seasons and the significantly
reduced malaria transmission rate in 2008 and thus reduced
recruitment, which also appeared to affect the severity of
malaria in terms of parasite densities at first detection and
haemoglobin concentrations. However, CIs of the effect size in
the final multivariable analysis do not include the clinically sig-
nificant effect size included in the sample size calculation, and
thus our observation is unlikely to be due to a type II error as
a result of lack of power to detect a true effect.
▪ It is possible that the relatively low dose of CQ we used was
insufficient to mediate the effects that we were testing for and
we were unable to conduct pilot studies of CQ drug dosage
and duration to determine the potential best treatment regime
to test or of the timings of evaluation of possible mechanisms
of effect.
▪ The change in design in 2008 to all children receiving ACT
antimalarial treatment did not affect the analysis of the primary
outcome. The change did, however, limit our ability to deter-
mine the effect of initial antimalaria therapy on haemoglobin
response in the placebo group. An effect of antimalarial treat-
ment CQ on Hb when in the context of adequate parasite clear-
ance, as was observed, might have been expected to occur in
the early period of recovery.
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enrolled children with malaria were treated with ACT
and then randomised and followed up as before
(ﬁgure 1). A combination of active and passive case
detection was used to identify children in participating
communities with malaria using a standard case deﬁn-
ition of clinical malaria (see below).
The climate of this district is typical of sub-Sahelian
Africa with a long dry season lasting from November to
June and a relatively short rainy season lasting from July
to October. Malaria transmission is seasonal, hyperen-
demic and follows the rainy season, occurring between
July and December. The prevalence of children experi-
encing one or more malarial episodes among a cohort
of 1002 children aged between 1 and 6 years under
active malaria surveillance during a population-based
study in 2003 was 34% (Doherty et al, unpublished
data). During the study period, standard malaria control
activities in the district consisted of insecticide-treated
bednet distribution and case ﬁnding and treatment. In
2008, the standard ﬁrst-line antimalarial treatment
regimen for uncomplicated malaria in the Gambia was
changed from CQ-SP to co-artemether.
Inclusion and exclusion criteria
Eligibility for malaria surveillance and subsequent pos-
sible enrolment into the RCT included all children in
the participating communities, aged between 12 and
72 months, at the start of the surveillance period and
who were not severely wasted, deﬁned as weight-for-
height Z scores less than −3SD.
Inclusion criteria for enrolment included: (1) uncom-
plicated malaria at day 0, deﬁned as a history of fever
48 h prior to presentation or a measured temperature of
37.5°C or more with peripheral parasitaemia (asexual
forms of Plasmodium falciparum ≥500/μL by microscopy)
on day 0 of the study and (2) for randomisation to the
postmalarial intervention, children had to have an Hb
between 69 and 110 g/L on day 3 with no peripheral
parasitaemia.
Children were excluded from the RCT if they were:
(1) unable to take oral medications; (2) had features of
severe malaria1; (3) had a known haemoglobinopathy;
(4) were enrolled in another project; (5) had already
received antimalarial drugs from other sources outside
the project team or (6) were prescribed other drugs
with potential antimalarial or antianaemic effects such
as co-trimoxazole and haematinics.
Following randomisation to weekly CQ or placebo,
children were withdrawn from the study if: (1) they
developed a second malarial episode or had life-
threatening symptoms, more severe disease or serious
adverse reactions; (2) left the study area for more than
14 days; (3) received antimalarials from other sources or
(4) their Hb fell below 70 g/L.
Figure 1 CONSORT flow diagram describing participants’ movements in 2007 and 2008.
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Field and clinical procedures
To effect the surveillance protocol, the study villages
were divided into geographically adjacent clusters super-
vised by a resident study nurse who visited each village
morning and evening and provided 24 h clinical cover-
age to all enrolled children in their cluster. The active
surveillance consisted of twice weekly temperature moni-
toring of enrolled children by village assistants, while the
passive surveillance consisted of mothers referring
sick children to the visiting study nurse. Children with
fever—reported or measured—were screened for
malaria using a rapid diagnostic test (MRDT; Cortez
diagnostics, Inc) after clinical evaluation. Children
testing negative to MRDT were treated based on the
likely diagnosis from the symptoms and signs. Children
testing positive to MRDT were started on antimalarials
immediately (either CQ-SP or ACT in 2007, and ACT in
2008 for 3 days) and directly observed by the study nurse
and managed as appropriate. Finger prick blood
samples (days 7, 15, 30 and 70) were collected in an
EDTA microtainer while venous blood (2 mL—days 0
and 90; and 5 mL—days 3 and 45) samples were col-
lected in an EDTA vacutainer and sent to the study
laboratory on the same day. Comorbidities were treated
as appropriate, avoiding co-trimoxazole and haematinics.
For the subsequent visits after initial malaria diagnosis at
day 0, children were seen by the study nurse and blood
samples and clinical data collected as per protocol. Only
children who fulﬁlled the inclusion criteria for advance-
ment to the weekly chloroquine/weekly placebo phase
of the study were sampled after day 3. These children
were also followed up on days 15, 30, 45, 70 (except in
2008) and 90.
Randomisation and blinding
The randomisation to malaria treatment group in 2007
(CQ-SP or ACT) was open (non-blinded to trial staff,
investigators or participants) and was carried out by
sequential assignment as children were identiﬁed. The
block randomisation to the postmalaria treatment of
weekly CQ or placebo in both 2007 and 2008 was
double blinded and was carried out in blocks of eight.
The randomisation codes were generated by a staff
member independent of the study team and held by the
external trial monitor. Treatment codes were labelled A
to H and placed in sequentially numbered, opaque
sealed envelopes held by the study nurses. Allocation to
the treatment was by matching the code in the envelope
to a bottle of the intervention labelled with the same
code and then labelled with the subject ID.
Interventions
Children openly randomised to malaria treatment at day
0 with CQ-SP received choroquine syrup (Chlormal,
Medreich Sterilab Ltd, Avalahalli, Bangalore, India) con-
sisting of 50 mg chloroquine base per 5 mL as chloro-
quine phosphate at a dose of 10 mg/kg for 3 days (days
0–2). SP (Micro Laboratories, India) was
co-administered as a 525 mg tablet (500 mg sulfadoxine
and 25 mg pyrimethamine) on day 0 only at a dose of
half tablet/10 kg. Children who were randomised to
ACT treatment in 2007 and all children in 2008 received
co-artemether (Coartem) tablets (Beijing Novartis
Pharma Ltd, Beijing China for Novartis Pharma AG,
Basle, Switzerland) as blister packets of six tablets per
card with each tablet containing 20 mg artemether and
120 mg lumefantrine. The treatment dose comprised a
stat dose on day 0 and then 8 h later, followed by twice
daily doses for the next 2 days with doses depending on
body weight (5 for <15 kg, 1 tablet/dose; 15 for <25 kg,
2 tablets/dose; 25 for <35 kg, 3 tablets per dose).
During the second blinded phase of the trial, children
received either weekly CQ syrup (as above) but at a dose
of 5 mg/kg or matching placebo syrup (prepared by the
Royal Victoria Teaching Hospital pharmaceutical labora-
tory in collaboration with Atlantic Pharmaceuticals
Limited, Latrikunda Sabiji, The Gambia) The syrups
were in similar amber-coloured bottles with matching
caps and labels. Doses were administered in the child’s
home under direct observation by the study nurses who
waited for at least 10 min after administering the drugs
to ensure that they were not vomited.
Primary and secondary outcomes
The primary outcome measure was Hb change from day
3 post-treatment of the malarial episode to day 90 in the
weekly CQ and placebo arms.
The secondary outcomes were to compare between the
weekly CQ and placebo arms: (1a) changes in erythropoi-
etic response between days 3 and 30; and (1b) between
days 3 and 90; (2) changes in urinary neopterin from
days 3 to 30 as a marker of macrophage activation; (3)
prevalence of submicroscopic malaria parasitaemia using
PCR at each time point and (4) Hb change from days 3
to 90 in the two placebo arms to investigate the effects of
initial malaria treatment therapy.
Sample size
During the initial study design, we used a working
assumption of an SD for change in Hb of 15 g/L.23 With
power 80% and signiﬁcance level set at 5%, we estimated
the sample sizes required to detect varying effect sizes
for the primary outcome. A sample size of 65 per
arm was estimated to be able to detect an effect size of
7.5 g/L. This sample size was thought to be achievable
and the effect size of likely public health signiﬁcance.
Laboratory procedures
Table 1 describes the different laboratory analyses con-
ducted. Zinc protoporphyrin (ZnPP) as a marker of iron
status was measured on fresh whole blood using a ﬂuor-
ometer (AVIV Biomedicals, Lakewood, New Jersey,
USA). Full blood count (FBC), haemoglobin and auto-
mated reticulocyte count were performed using a Cell
Dyne 3700 (Abbott Laboratories, Abbott Park, Illinois,
USA). Iron deﬁciency was deﬁned using three
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parameters: mean cell volume (MCV), mean cell haemo-
globin (MCH) and ZnPP. The cut-off values for the dif-
ferent parameters employed were: ≥61 μmol/mol of Hb
for ZnPP,24 ≤73 fL for MCV25 and ≤25 pg for MCH.25
Combining these parameters has been shown to
increase their sensitivity and speciﬁcity to identify iron
deﬁciency.26 Malarial parasites were identiﬁed in a thick
peripheral blood smear stained with Giemsa overnight
and read by a light microscope with ×100 magniﬁcation
in oil immersion. Parasite DNA extraction and subse-
quent quantitative PCR ampliﬁcation were carried out
using established protocols.27 In brief, DNA extraction
was carried out using the QIamp DNA Mini Kit (Qiagen
Ltd, UK) according to the manufacturer’s instructions
with minor modiﬁcations. Extracted DNA samples were
stored at −20°C. Quantiﬁcation of parasite density was
performed with a TaqMan assay employing a ﬂuorogenic
probe to detect speciﬁc parasite products and using an
Opticon 2 Real Time PCR machine and Opticon V.3.1
software (Bio-Rad Laboratories, Inc). Primers and
probes were synthesised by Applied Biosystems, UK.
Urinary neopterin levels were measured using an ELISA
technique (BRAHMS Neopterin EIA, B.R.A.H.M.S,
Germany). The stored urine was allowed to thaw at
room temperature and then diluted 1 : 100, and the rest
of the procedure was according to the manufacturer’s
instructions.
Statistical analysis
Delta haemoglobin summary statistics are presented as
means and SDs for normally distributed continuous vari-
ables, and counts and percentages for discrete variables.
Neopterin and parasite count were not normally distrib-
uted and were log transformed (loge for neopterin and
log10 for parasite count). The geometric means and
95% CIs are presented for log-transformed variables.
Two-sided Student t tests were used to compare results
between two treatment arms.
Visual inspection of Hb change between baseline at day
3 and later time points by treatment arm suggested that,
by day 30, Hb change in both treatment arms had
reached a plateau. To fully determine the effect of treat-
ment group on Hb change, we used random effects
models using the repeat measures at days 30 and 90.
Initial malaria treatment group (CQ-SP vs ACT), Hb at
recruitment (day 0 Hb), baseline Hb (day 3), age in
months, year of study, and the child’s village were
included in the models ‘a priori’ and hence adjusted for.
Linear regression was used to investigate further
potential predictors of Hb change in the study popula-
tion. First, simple linear regression was used to assess the
association of each predictor variable with Hb.
Thereafter, all variables with a p value of 0.1 or less were
included in a multiple linear regression to assess con-
founding. The ﬁnal regression model consisted of only
the variables that maintained a signiﬁcant association
with Hb in the multiple regression models. All analyses
were carried out using STATA V.8 (StataCorp, College
Station, Texas, USA).
Ethical clearance
The Scientiﬁc Coordinating Committee of the Medical
Research Council (UK), The Gambia, and the MRC/
Gambia Government Joint Ethical Committee approved
the study (SCC 1076). Written informed consent was
obtained from parents/guardians of the children prior
to enrolment. The clinical trial registration number is
NCT00473837 (ClinicalTrials.gov).
RESULTS
Characteristics of the study population under malaria
surveillance
Figure 1 describes the ﬂow of participants through the
study and the reasons for exclusions from the study. In
2007, 1445 of 1817 (80%) potentially eligible children
identiﬁed through the Keneba MRC DSS database from
14 villages were included in the malaria surveillance. In
2008, 1220 of the 1413 (86%) identiﬁed children from
ﬁve of the original villages were included in the malaria
surveillance (smaller villages were excluded as they had
contributed few cases in 2007). Table 2 describes the
characteristics of the children placed under surveillance
for malaria. The proportion of children with a positive
malaria rapid test during surveillance (only ﬁrst event
per child counted) fell from 7.3% (105/1445) in 2007
Table 1 Laboratory investigations conducted
Investigations Specimen Days collected* Purpose
Microscopy for malaria parasite Blood 0, 3, 7, 15, 30, 45, 70 and 90 To assess parasitaemia
Erythrocyte zinc protoporphyrin Blood 0 and 3 To assess iron status
Full blood count Blood 0, 3, 7, 15, 30, 45, 70 and 90 To assess Hb change over time
Automated reticulocyte percentage Blood 3, 7, 15, 30, 45, 70 and 90 To monitor bone marrow response
Quantitative PCR for Plasmodium
falciparum parasites
Blood 0, 3, 7, 15, 30, 45, 70 and 90 To assess submicroscopic parasitaemia
Urinary neopterin concentration Urine 3, 15 and 30 To assess macrophage activation as
measure of immune-mediated inflammation
*No blood was collected on days 7 and 70 in 2008.
Hb, haemoglobin.
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to 4% (49/1220) in 2008. In the ﬁrst year of the study,
101 (96%) of the children with a positive malaria rapid
test were randomised to CQ-SP or ACT treatment, and
65 (64%) subsequently randomised at day 3 to weekly
chloroquine or placebo, with all children completing
follow-up until day 30 and 33/34 completing follow-up
until day 90 in the weekly CQ and 28/31 in the weekly
placebo group. In the second year of the study, 31 of the
49 (63%) cases with a ﬁrst positive malaria rapid test
were subsequently randomised to weekly CQ or placebo
after treatment with ACT, all of whom completed
follow-up until day 90 (16 CQ and 15 placebo). Thus, 96
children were included in the analysis of the primary
and secondary outcomes, except for the analysis of
effect of initial malaria treatment within the placebo
arms which included 31 children.
Table 3 describes the characteristics of participants
randomised to weekly chloroquine and weekly placebo
for both years combined. Demographic and anthropo-
metric characteristics were similar between the groups as
was baseline Hb at day 3. The prevalence of iron deﬁ-
ciency measured at baseline was 43.1% (28/65) in 2007
and 58.1% (18/31) in 2008 with a similar prevalence
between the CQ/placebo groups within each year (data
not shown) and in both years combined. However, para-
site density was lower in the placebo group (table 3). No
adverse events were reported in either treatment group.
Effect of weekly CQ on haemoglobin change during
follow-up
To assess the effect of weekly chloroquine on Hb recov-
ery after clearance of peripheral parasitaemia, we com-
pared change in Hb from days 3 to 90 and from days 3
to 30 in the two arms. No signiﬁcant differences in Hb
change between the two groups were observed, either
for the data for both study years or for each study year
separately (both years combined: change in Hb at day
90, CQ +10.04 g/L (95% CI 6.66 to 13.42) vs placebo
+7.61 g/L (95% CI 2.88 to 12.35); ﬁgure 2). Thus, the
effect size of the CQ treatment was 2.43 g/L (95% CI
−3.38 to 8.24) compared to the 7.5 g/L we included in
the sample size calculation. However, at day 15, children
receiving weekly CQ had an increase of 3.5 g/L (95% CI
0.5 to 6.4) compared to 0.8 g/L (95% CI −2.3 to 3.9) in
children in the placebo arm, but this difference did not
reach statistical signiﬁcance (p=0.2). The lack of effect
of weekly CQ remained when adjusting for factors deter-
mined ‘a priori’ (Hb at recruitment (day 0), Hb at base-
line (day 3), age (in months), year of study, initial
treatment received (CQ-SP vs ACT) and village group)
using a random effects repeated measures model includ-
ing Hb measured at days 30 and 90 (coefﬁcient=1.43
(95% CI −1.70 to 4.57). Furthermore, adding parasite
density at recruitment, presence of submicroscopic
parasitaemia at any time point during follow-up, and
Table 3 Baseline characteristics of children randomised to weekly chloroquine and weekly placebo in 2007 and 2008,
pooled
Parameter
Chloroquine group
N=50
Placebo group
N=46
Male sex (%) 28 (56.0) 24 (52.2)
Age in months, mean (SD) 41.9 (18.1) 38.7 (17.8)
Height-for-age Z scores, mean (SD) −1.19 (0.91) −0.94 (1.20)
Weight-for-age Z scores, mean (SD) −1.44 (0.95) −1.35 (0.87)
Weight-for-height Z scores, mean (SD) −0.94 (0.90) −0.96 (0.79)
BMI (kg/m2), mean (SD) 14.7 (1.4) 14.7 (1.3)
Parasite density at recruitment (day 0), geometric mean, (95% CI) 47 783 (31 617 to 71 120) 32 496 (21 910 to −47 507)
Hb (g/L) at recruitment (day 0), mean (SD) 103.9 (14.2) 101.5 (14.8)
Hb (g/L) at baseline (day 3), mean (SD) 93.4 (9.6) 93.7 (10.2)
Iron deficient* at baseline (day 3) (%) 23 (46) 23 (50)
*Iron deficiency was defined as zinc protoporphyrin ≥61 μmol/mol of Hb, mean cell volume ≤73 fL and mean cell haemoglobin ≤25 pg.
Table 2 Baseline characteristics of all participants under surveillance
2007 2008 Combined
N=1445 N=1220 N=2665
Mean age in months (SD) 42.2 (17.2) 40.7 (17.7) 41.5 (17.5)
Mean weight-for-height Z scores (SD) −1.06 (0.84) −1.02 (0.85) −1.04 (0.84)
Mean weight-for-age Z scores (SD) −1.48 (0.97) −1.50 (0.94) −1.49 (0.95)
Mean height-for-age Z scores (SD) −1.06 (1.21) −1.17 (1.13) −1.11 (1.17)
Mean body mass index (kg/m2) (SD) 14.6 (1.3) 14.7 (1.4) 14.6 (1.4)
Prevalence of a malaria rapid test positive result during surveillance* 105 (7.3) 49 (4.0) 154 (5.8)
*Only the first positive result is counted.
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presence of iron deﬁciency had no effect on the esti-
mates of effect for CQ vs placebo treatment during
follow-up (data not shown).
Predictors of haemoglobin at day 90
In the absence of an effect of weekly CQ on Hb change
after successful malaria treatment, we assessed what
other factors might determine ﬁnal Hb. Using simple
linear regression, signiﬁcant positive associations were
observed for parasite density at day 0, better nutritional
status, age, Hb at day 0 at malaria diagnosis and day 3 of
successful treatment. Presence of iron deﬁciency at base-
line was associated with signiﬁcantly lower ﬁnal Hb.
There was no apparent effect of initial malaria treatment
(CQ-SP vs ACT; table 4). In a ﬁnal multiple regression
model, Hb at day 0 was the strongest predictor of ﬁnal
Hb and other independent predictors of ﬁnal haemo-
globin were presence of iron deﬁciency at day 3, degree
of stunting (height-for-age Z score), and age (in
months). Children with higher Hb at diagnosis and
older children had greater ﬁnal Hb. Children with iron
deﬁciency at day 3 had signiﬁcantly lower ﬁnal Hb with
a mean difference of 12.1 g/L (table 5).
Effect of initial antimalaria treatment (CQ-SP vs ACT) on
haemoglobin change
A secondary outcome of this study was Hb change from
days 3 to 30 and day 90 in the placebo arm to determine
whether initial antimalaria treatment (CQ-SP or ACT)
treatment affected macrophage iron loading in acute
clinical malaria and its subsequent release. As indicated
in the analysis of Hb at day 90, there was no signiﬁcant
effect of inital antimalarial treatment. Please see online
supplementary ﬁgure S1 depicting Hb change during
follow-up from days 0 to 90 in the placebo arm by initial
antimalarial treatment received and the accompanying
text.
Submicroscopic parasitaemia, inflammation, bone marrow
response, haemoglobin change and treatment groups
Submicroscopic parasitaemia was commonest in the ﬁrst
7 days of acute phase follow-up (days 3–15). By day 30,
most were negative (77%). The prevalence of submicro-
scopic parasitaemia at days 30 and 90 combined was
15.1% and there was no evidence of an effect of the post-
malaria treatment group or of initial antimalarial treat-
ment (ﬁgure 3 and see online supplementary ﬁgure S2).
Most of the submicroscopic parasitaemia at these time
points was of a very low level (1–2 parasites/μL).
However, higher parasite density at diagnosis was asso-
ciated with an increased likelihood of subsequent sub-
microscopic parasitaemia at days 30 or 90 with a one-log
increase in parasite count increasing the odds of having
submicroscopic parasitaemia by 1.6 (p=0.005). Although
the presence/absence of submicroscopic parasitaemia
Table 4 Predictors of final haemoglobin at day 90 using univariable linear regression
Parameter Regression coefficient (95% CI) p Value
Parasite count at recruitment (day 0) 3.5 (1.1 to 5.8) 0.004
Sex −0.4 (−3.3 to 2.5) 0.8
Iron deficiency at baseline (day 3) −12.1 (−14.7 to −9.5) <0.001
Height-for-age Z scores (HAZ) <−2 3.2 (1.8 to 4.6) <0.001
Weight-for-age Z scores (WAZ) <−2 2.6 (1.0 to 4.2) 0.001
Weight-for-height (WHZ) Z scores <−2 0.1 (−1.6 to 1.8) 0.9
Age in months 0.4 (0.3 to 0.4) <0.001
Initial antimalaria treatment arm 1.2 (−2.1 to 4.4) 0.5
CQ vs placebo randomisation group −0.5 (−3.4 to 2.5) 0.8
Hb (g/L) at recruitment (day 0) 0.6 (0.5 to 0.6) <0.001
Hb (g/L) at baseline (day 3) 0.7 (0.6 to 0.8) <0.001
Village 1.9 (0.9 to 3.0) <0.001
Presence of sub-microscopic parasitaemia at any time point during follow-up 0.6 (−7.1 to 8.2) 0.9
Year of study −1.3 (−4.4 to 1.8) 0.4
Figure 2 Mean change in haemoglobin concentration at
days 30 and 90 from baseline at day 3 by treatment group for
each year of study and for both years combined. Error bars
represent the 95% CIs. Change in haemoglobin at day 3 is
compared to haemoglobin concentration at presentation with
malaria and initiation of antimalarial treatment. Thereafter, the
comparison is with baseline levels at day 3 after completion of
antimalarial treatment. Error bars represent the 95% CIs.
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during follow-up (days 30 and 90) was not associated
with ﬁnal Hb (tables 4 and 5), in children with high
qPCR (quantitative PCR parasite count) parasite count
(>500/μL, N=3) at day 30, Hb at day 30 was signiﬁcantly
lower compared to children with 1–2 parasites/μL or
none at day 30 (82.3 vs 102.8 g/L; p=0.01). Similarly, the
mean Hb change was also reduced in those with persist-
ent high parasitaemia at day 30 (−5.0 vs 8.5 g/L; mean
Hb difference (95% CI) 13.5 g/L (−0.3 to 27.3);
p=0.06). Bone marrow response as assessed by the per-
centage of reticulocytes peaked at day 15 (4.5% in both
treatment groups combined), compared to similar levels
of around 2% at all other measured time points (days 3,
7, 15 and 90). There was no evidence of an effect of
either the postmalaria treatment group (ﬁgure 4) or of
the initial antimalarial therapy (data not shown) on
bone marrow response. Urinary neopterin, a product of
activated macrophages and therefore a marker of a
pro-inﬂammatory immune status, was strongly associated
with qPCR parasite count at day 30 (regression coefﬁ-
cient: 0.2 (95% CI 0.08 to 0.33), p=0.003; adjusted
R2=0.4091) and was also associated with Hb at day 30.
There was no evidence of an effect of the postmalaria
treatment group (ﬁgure 5) or of the initial antimalarial
treatment on neopterin concentrations (see online sup-
plementary ﬁgure S3).
DISCUSSION
Chloroquine is used in the treatment of several diseases
in addition to its antimalarial use.28 29 However, we
believe this to be the ﬁrst study to assess its potential
role in the management of postmalarial anaemia. We
hypothesised that since malarial anaemia is essentially a
systemic inﬂammatory response to infection,12 chloro-
quine, by suppressing plasmodium-induced inﬂamma-
tion, could enhance erythropoietic recovery. We tested
this hypothesis by comparing two groups of children—
one group receiving weekly chloroquine and the other
group weekly placebo after complete clearance of per-
ipheral parasitaemia as determined by microscopy. The
primary outcome measure was the recovery in Hb at
days 30 and 90 compared to the day 3 Hb levels. Our
results showed no signiﬁcant difference in the Hb
change between the two groups. The data were interro-
gated further by a random effects model modelling data
at days 30 and 90 simultaneously while adjusting for Hb
at day 3 and taking into account random measurement
errors and missing data. This conﬁrmed that weekly
chloroquine at 5 mg/kg body weight did not improve
Hb recovery after uncomplicated clinical malaria. There
was a suggestion that weekly CQ may have increased the
rate of recovery in Hb change at day 15 accompanied by
non-signiﬁcantly increased reticulocyte percentage.
A limitation of the study was the need to recruit parti-
cipants over two malaria transmission seasons. In 2008,
there was a reduced malaria transmission rate, and thus
there were fewer cases available for recruitment and also
an apparent effect on the severity of malaria in terms of
parasite densities at ﬁrst detection and effect on
Figure 4 Reticulocyte percentage as an indicator of bone
marrow response by treatment group for both years
combined.
Table 5 Independent predictors of final haemoglobin (day 90) using multivariable linear regression
Parameter Regression coefficient (95% CI) p Value
Day 0 Hb 0.44 (0.36 to 0.52) <0.001
Presence of iron deficiency −3.0 (−5.57 to −0.43) 0.022
Height-for-age Z score <−2 1.48 (0.41 to 2.56) 0.007
Age in months 0.21 (0.14 to 0.28) <0.001
Model: adjusted r2=0.46, F=76.6, p>F<0.001.
Hb, haemoglobin.
Figure 3 Percentage of participants with submicroscopic
malaria (qPCR) over time by postmalarial treatment group.
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haemoglobin concentrations, with a signiﬁcantly higher
baseline Hb in 2008. However, the change in design that
was necessitated in 2008 did not change the primary
outcome analysis. Furthermore, CIs of the observed
effect size in the ﬁnal multivariable analysis do not
include the effect size included in the sample size calcu-
lation, and thus our observation is unlikely to be due to
a type II error as a result of lack of power to detect a
true effect of this magnitude.
The change in design in 2008 to all children receiving
ACT antimalarial treatment did not affect the analysis of
the primary outcome. The change did, however, limit
our ability to determine the effect of initial antimalaria
therapy on haemoglobin response in the placebo group.
An effect of antimalarial treatment CQ on Hb when in
the context of adequate parasite clearance, as was
observed, might have been expected to occur in the
early period of recovery.
The recommended anti-inﬂammatory dose of CQ is
3–4 mg/kg/day. However, owing to a lack of safety data
for this condition and considering the potential adverse
effects, particularly retinal damage, we used the lower
prophylactic dose of 5 mg/kg/week. Using this low dose
might have contributed to our inability to detect an
effect of CQ. Drenou et al30 reported the successful
long-term control of sideroblastic anaemia (a condition
of reduced incorporation of iron into haem in the pres-
ence of sufﬁcient or high iron) in an adult patient using
chlrorquine but at 100 mg/day.
We had hypothesised that chloroquine will impede
macrophageal iron sequestration during the acute clin-
ical episode and improve iron availability for the process
of erythropoiesis. Urinary excretion of neopterin is
markedly increased in individuals infected with malaria,
and corresponds to the concurrent activation of T cells
and macrophages.31–33 We measured the urinary neop-
terin at days 3, 15 and 30 and expected to see a more
rapid decline in the neopterin level in the weekly
chloroquine group than in the weekly placebo group,
but no difference was observed between the treatment
groups. It is possible that a difference may have occurred
at an intermediate time point between days 3 and 15,
when the levels had already almost normalised. Indeed,
Brown et al33 showed that in a group of volunteers
experimentally infected with plasmodium parasites, the
timing of maximum neopterin excretion coincided with
the treatment and elimination of parasitaemia. In our
study, this would coincide with study days 0–3. In future,
it might be more informative to carry out more measure-
ments during the ﬁrst week of malaria diagnosis.
The participants were followed up for 90 days because
the reports had suggested that Hb continues to fall even
after successful malaria treatment primarily due to con-
tinuing inﬂammation.34 35 In this study, we found no evi-
dence of persistent inﬂammation, except in the few
cases with remaining parasitaemia at day 30, which also
had decreased absolute Hb and Hb change at day 30
compared with children with no parasitaemia or parasite
counts of 1–2/μL.
Our observation that children with higher Hb at diag-
nosis had greater Hb recovery is potentially paradoxical
as one would have expected the reverse through statis-
tical regression to the mean and a greater ‘catch up’ in
children with a lower starting Hb at day 3. However, as
the majority of iron used for Hb recovery is recycled,24
those with higher Hb at day 0 have more iron available
for recovery. Our non-provision of exogenous iron
during the study may have restricted the ability of the
more anaemic children to respond appropriately, as sug-
gested by our observation of reduced Hb recovery in
children with apparent iron deﬁciency at day 0. An
earlier study in Gambian children showed improved
haematological recovery in children treated for malaria
and cosupplemented with iron compared to placebo.36
However, we have also shown in Gambian children
reduced iron absorption from supplementation in post-
malarial anaemia, while also experiencing greater Hb
recovery compared to supplemented children with iron-
deﬁciency anaemia, thus causing us to question the efﬁ-
cacy of iron supplementation given within 2 weeks of
antimalarial treatment.24 Without the inclusion of a
further randomised treatment arm of postmalarial treat-
ment iron supplementation, it is not possible to make
further recommendations concerning the recent argu-
ment for the provision of iron supplementation to chil-
dren in malaria endemic areas with regular malaria
surveillance and treatment facilities.37
Our ﬁnding that stunted children recovered Hb
poorly is consistent with an earlier report of stunting
being a determinant of the severity of malaria-associated
anaemia.38 In our population, this effect was independ-
ent of iron status.
Age has been shown to be strongly associated with risk
of severe anaemia in children with acute malaria, the
risk decreasing with increasing age.39 In addition, we
have shown in this study that older children recover
better from anaemia after an acute malaria episode than
younger children. Paying special attention to younger
children with malarial anaemia could reduce malaria-
related mortality in children.
Figure 5 Urinary neopterin by postmalarial treatment group.
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In conclusion, weekly chloroquine administered for
3 months to children with mild malarial anaemia at a
dose of 5 mg/kg/week resulted in no improvement in
erythropoietic recovery compared to placebo. Older chil-
dren and children with higher initial Hb, less stunting at
diagnosis and without iron deﬁciency had better Hb
recovery postmalaria. Similar to other reports in the lit-
erature, urinary neopterin was elevated during acute
malaria. The role of iron deﬁciency in erythropoietic
recovery postmalaria noted in this study suggests areas
for further detailed investigation of the clinical value in
administering both antimalarial and iron supplementa-
tion to children with malarial anaemia residing in areas
of high iron deﬁciency and malaria burden.
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